The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced.

In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €182.00. The company’s shares ...